Immunotherapy plus chemotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy to shrink inoperable stage IIIC lung cancer. The goal is to make the cancer small enough to remove with surgery and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer (NSCLC) that has not been treated before and cannot currently be removed by surgery
- Your cancer is stage IIIC and has measurable tumors that can be seen on imaging
- You do not have certain genetic mutations (EGFR or ALK) in your cancer
- You are willing to have surgery if the treatment shrinks your cancer enough to make it removable
- Your overall health and organ function are good enough for treatment (ECOG score 0–1)
- You have not received any immunotherapy or checkpoint inhibitor drugs before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This trial uses a freezing technique (cryoablation) through a bronchoscope to shrink tumors blocking the main airways. It is combined with standard chemotherapy and immunotherapy (pembrolizumab) to treat advanced lung cancer that hasn't been treated before.
This trial tests a combination of chemotherapy and an immunotherapy drug called sintilimab to shrink unresectable stage IIIB-IIIC non-small cell lung cancer, making it possible to remove it with surgery. The goal is to see if this approach can help patients who aren't candidates for surgery now become candidates later.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.